Identification

Name
Aclidinium
Accession Number
DB08897
Type
Small Molecule
Groups
Approved
Description

Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.

Structure
Thumb
Synonyms
  • Aclidinium
External IDs
LAS-34273
Product Ingredients
IngredientUNIICASInChI Key
Aclidinium BromideUQW7UF9N91320345-99-1XLAKJQPTOJHYDR-QTQXQZBYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bretaris Genuair322 μgRespiratory (inhalation)Astra Zeneca Ab2012-07-20Not applicableEu
Bretaris Genuair322 μgRespiratory (inhalation)Astra Zeneca Ab2012-07-20Not applicableEu
Bretaris Genuair322 μgRespiratory (inhalation)Astra Zeneca Ab2012-07-20Not applicableEu
Eklira Genuair322 μgRespiratory (inhalation)Astra Zeneca Ab2012-07-20Not applicableEu
Eklira Genuair322 μgRespiratory (inhalation)Astra Zeneca Ab2012-07-20Not applicableEu
Eklira Genuair322 μgRespiratory (inhalation)Astra Zeneca Ab2012-07-20Not applicableEu
Tudorza GenuairPowder, metered400 mcgRespiratory (inhalation)Astra Zeneca2013-09-13Not applicableCanada
Tudorza PressairInhalant400 ug/1Respiratory (inhalation)Forest Laboratories2012-07-232017-12-22Us
Tudorza PressairInhalant400 ug/1Respiratory (inhalation)Astra Zeneca Lp2015-07-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Duaklir GenuairAclidinium Bromide (400 mcg)Powder, meteredRespiratory (inhalation)Astra Zeneca2015-07-09Not applicableCanada
Duaklir GenuairAclidinium Bromide (340 μg) + Formoterol fumarate (12 μg)Respiratory (inhalation)Astra Zeneca Ab2014-11-19Not applicableEu
Duaklir GenuairAclidinium Bromide (340 μg) + Formoterol fumarate (12 μg)Respiratory (inhalation)Astra Zeneca Ab2014-11-19Not applicableEu
Duaklir GenuairAclidinium Bromide (340 μg) + Formoterol fumarate (12 μg)Respiratory (inhalation)Astra Zeneca Ab2014-11-19Not applicableEu
International/Other Brands
Bretaris Genuair / Eklira Genuair
Categories
UNII
K17VY42F6C
CAS number
727649-81-2
Weight
Average: 484.651
Monoisotopic: 484.161624833
Chemical Formula
C26H30NO4S2
InChI Key
ASMXXROZKSBQIH-VITNCHFBSA-N
InChI
InChI=1S/C26H30NO4S2/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2/q+1/t20?,22-,27?/m0/s1
IUPAC Name
(3R)-3-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azabicyclo[2.2.2]octan-1-ium
SMILES
OC(C(=O)O[[email protected]]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1

Pharmacology

Indication

Aclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Structured Indications
Pharmacodynamics

Aclidinium does not prolong the QTc interval or have significant effects on cardiac rhythm.

Mechanism of action

Aclidinium is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. Aclidinium's effects on the airways are mediated through the M3 receptor at the smooth muscle to cause bronchodilation. Prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
AMuscarinic acetylcholine receptor M2
antagonist
Human
AMuscarinic acetylcholine receptor M3
antagonist
Human
AMuscarinic acetylcholine receptor M4
antagonist
Human
AMuscarinic acetylcholine receptor M5
antagonist
Human
Absorption

Bioavailability, healthy subjects = 6%; T max, healthy subjects = 10 minutes; Time to steady state, healthy subjects = 2 days;

Volume of distribution

Following IV administration, the volume of distribution is 300 L

Protein binding
Not Available
Metabolism

The major route of metabolism of aclidinium bromide is hydrolysis, which occurs both chemically and enzymatically by esterases in the plasma. Aclidinium bromide is rapidly and extensively hydrolyzed to its alcohol and dithienylglycolic acid derivatives, neither of which binds to muscarinic receptors and are pharmacologically inactive.

Route of elimination

Intravenously administered radiolabelled aclidinium bromide was administered to healthy volunteers and was extensively metabolized with 1% excreted as unchanged aclidinium. Approximately 54% to 65% of the radioactivity was excreted in urine and 20% to 33% of the dose was excreted in feces. The combined results indicated that almost the entire aclidinium bromide dose was eliminated by hydrolysis. After dry powder inhalation, urinary excretion of aclidinium is about 0.09% of the dose.

Half life

Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). Effective half-life = 5-8 hours.

Clearance

Total clearance, IV dose, young healthy subjects = 170 L/h (inter-individual variability of 36%)

Toxicity

Most common adverse reactions (≥3% incidence and greater than placebo) are headache, nasopharyngitis and cough.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AlcuroniumAlcuronium may increase the anticholinergic activities of Aclidinium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Ambenonium.Approved
AmoxapineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Amoxapine.Approved
Anisotropine MethylbromideAnisotropine Methylbromide may increase the anticholinergic activities of Aclidinium.Approved
AtracuriumAtracurium may increase the anticholinergic activities of Aclidinium.Approved, Experimental, Investigational
Atracurium besylateAtracurium besylate may increase the anticholinergic activities of Aclidinium.Approved
AtropineAtropine may increase the anticholinergic activities of Aclidinium.Approved, Vet Approved
BenactyzineBenactyzine may increase the anticholinergic activities of Aclidinium.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Aclidinium.Approved
BenzatropineBenzatropine may increase the anticholinergic activities of Aclidinium.Approved
BezitramideThe risk or severity of adverse effects can be increased when Aclidinium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenBiperiden may increase the anticholinergic activities of Aclidinium.Approved, Investigational
BornaprineBornaprine may increase the anticholinergic activities of Aclidinium.Experimental
Botulinum Toxin Type AAclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BAclidinium may increase the anticholinergic activities of Botulinum Toxin Type B.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineButylscopolamine may increase the anticholinergic activities of Aclidinium.Approved, Investigational, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Aclidinium.Approved, Vet Approved
ChlorphenoxamineChlorphenoxamine may increase the anticholinergic activities of Aclidinium.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Aclidinium.Approved
CimetropiumAclidinium may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CodeineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Aclidinium.Experimental
CyclopentolateCyclopentolate may increase the anticholinergic activities of Aclidinium.Approved
DarifenacinDarifenacin may increase the anticholinergic activities of Aclidinium.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Demecarium.Approved
DesloratadineDesloratadine may increase the anticholinergic activities of Aclidinium.Approved, Investigational
DexetimideDexetimide may increase the anticholinergic activities of Aclidinium.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineDicyclomine may increase the anticholinergic activities of Aclidinium.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydromorphine.Experimental, Illicit
DiphenhydramineDiphenhydramine may increase the anticholinergic activities of Aclidinium.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Aclidinium is combined with DPDPE.Experimental
DronabinolAclidinium may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Edrophonium.Approved
EluxadolineAclidinium may increase the constipating activities of Eluxadoline.Approved, Investigational
EmeproniumEmepronium may increase the anticholinergic activities of Aclidinium.Experimental
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Aclidinium.Experimental
EtanautineEtanautine may increase the anticholinergic activities of Aclidinium.Experimental
EthopropazineEthopropazine may increase the anticholinergic activities of Aclidinium.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineEtybenzatropine may increase the anticholinergic activities of Aclidinium.Experimental
FentanylThe risk or severity of adverse effects can be increased when Aclidinium is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineFesoterodine may increase the anticholinergic activities of Aclidinium.Approved
FlavoxateFlavoxate may increase the anticholinergic activities of Aclidinium.Approved
GalantamineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Galantamine.Approved
GallamineGallamine may increase the anticholinergic activities of Aclidinium.Experimental
Gallamine TriethiodideGallamine Triethiodide may increase the anticholinergic activities of Aclidinium.Approved
Glucagon recombinantThe risk or severity of adverse effects can be increased when Aclidinium is combined with Glucagon recombinant.Approved
GlycopyrroniumGlycopyrronium may increase the anticholinergic activities of Aclidinium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Aclidinium is combined with Heroin.Approved, Illicit, Investigational
HomatropineHomatropine may increase the anticholinergic activities of Aclidinium.Approved
Human secretinThe therapeutic efficacy of Human secretin can be decreased when used in combination with Aclidinium.Approved
Huperzine AThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Huperzine A.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Aclidinium.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Aclidinium.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydromorphone.Approved, Illicit
HyoscyamineHyoscyamine may increase the anticholinergic activities of Aclidinium.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Aclidinium.Approved
IpidacrineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Aclidinium.Approved
IsoflurophateThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Aclidinium.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Ketobemidone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Lofentanil.Illicit
LoxapineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Loxapine.Approved
MalathionThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolMazaticol may increase the anticholinergic activities of Aclidinium.Experimental
MecamylamineMecamylamine may increase the anticholinergic activities of Aclidinium.Approved, Investigational
MefloquineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Mefloquine.Approved, Investigational
MemantineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineMethantheline may increase the anticholinergic activities of Aclidinium.Approved, Investigational
MethscopolamineMethscopolamine may increase the anticholinergic activities of Aclidinium.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Aclidinium.Approved
Methylscopolamine bromideMethylscopolamine bromide may increase the anticholinergic activities of Aclidinium.Approved
MetixeneMetixene may increase the anticholinergic activities of Aclidinium.Approved
MetoclopramideThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Aclidinium.Approved
MianserinMianserin may increase the anticholinergic activities of Aclidinium.Approved, Investigational
MinaprineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Aclidinium is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Morphine.Approved, Investigational
NabiloneAclidinium may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Opium.Approved, Illicit
OrphenadrineOrphenadrine may increase the anticholinergic activities of Aclidinium.Approved
OtiloniumOtilonium may increase the anticholinergic activities of Aclidinium.Experimental, Investigational
OxitropiumOxitropium may increase the anticholinergic activities of Aclidinium.Investigational
OxybutyninOxybutynin may increase the anticholinergic activities of Aclidinium.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumOxyphenonium may increase the anticholinergic activities of Aclidinium.Approved
PancuroniumPancuronium may increase the anticholinergic activities of Aclidinium.Approved
ParaoxonThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Pentazocine.Approved, Vet Approved
PentoliniumPentolinium may increase the anticholinergic activities of Aclidinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Phenazocine.Experimental
PhenglutarimidePhenglutarimide may increase the anticholinergic activities of Aclidinium.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Physostigmine.Approved, Investigational
PipecuroniumPipecuronium may increase the anticholinergic activities of Aclidinium.Approved
PirenzepinePirenzepine may increase the anticholinergic activities of Aclidinium.Approved
PiritramideThe risk or severity of adverse effects can be increased when Aclidinium is combined with Piritramide.Approved, Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Aclidinium.Approved
Potassium ChlorideAclidinium may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Aclidinium.Approved, Investigational
ProcyclidineProcyclidine may increase the anticholinergic activities of Aclidinium.Approved
PropanthelinePropantheline may increase the anticholinergic activities of Aclidinium.Approved
PropiverinePropiverine may increase the anticholinergic activities of Aclidinium.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Pyridostigmine.Approved, Investigational
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Aclidinium.Approved
QuinidineQuinidine may increase the anticholinergic activities of Aclidinium.Approved, Investigational
RamosetronAclidinium may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineScopolamine may increase the anticholinergic activities of Aclidinium.Approved, Investigational
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Aclidinium.Approved, Investigational
SolifenacinSolifenacin may increase the anticholinergic activities of Aclidinium.Approved
SufentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Sufentanil.Approved, Investigational
SulpirideAclidinium may increase the anticholinergic activities of Sulpiride.Approved, Investigational
TacrineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Tilidine.Experimental
TiotropiumTiotropium may increase the anticholinergic activities of Aclidinium.Approved
TolterodineTolterodine may increase the anticholinergic activities of Aclidinium.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Aclidinium.Approved, Vet Approved
TrihexyphenidylTrihexyphenidyl may increase the anticholinergic activities of Aclidinium.Approved
TrimethaphanTrimethaphan may increase the anticholinergic activities of Aclidinium.Approved, Investigational
TropatepineTropatepine may increase the anticholinergic activities of Aclidinium.Experimental
TropicamideTropicamide may increase the anticholinergic activities of Aclidinium.Approved, Investigational
TrospiumTrospium may increase the anticholinergic activities of Aclidinium.Approved
TubocurarineTubocurarine may increase the anticholinergic activities of Aclidinium.Approved
TyrothricinThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumAclidinium may increase the anticholinergic activities of Umeclidinium.Approved
VecuroniumVecuronium may increase the anticholinergic activities of Aclidinium.Approved
Food Interactions
Not Available

References

General References
  1. Reid DJ, Pham NT: Emerging Therapeutic Options for the Management of COPD. Clin Med Insights Circ Respir Pulm Med. 2013 Apr 9;7:7-15. doi: 10.4137/CCRPM.S8140. Print 2013. [PubMed:23641160]
  2. Cazzola M, Page CP, Matera MG: Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Jun;14(9):1205-14. doi: 10.1517/14656566.2013.789021. Epub 2013 Apr 9. [PubMed:23566013]
  3. Jones P: Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv Ther. 2013 Apr;30(4):354-68. doi: 10.1007/s12325-013-0019-2. Epub 2013 Apr 2. [PubMed:23553509]
External Links
KEGG Drug
D08837
PubChem Compound
11434515
PubChem Substance
175427140
ChemSpider
9609381
BindingDB
50296331
ChEBI
65346
ChEMBL
CHEMBL1194325
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Aclidinium_bromide
ATC Codes
R03AL05 — Formoterol and aclidinium bromideR03BB05 — Aclidinium bromide
AHFS Codes
  • 12:08.08 — Antimuscarinics Antispasmodics
FDA label
Download (1.25 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Not Yet RecruitingTreatmentPulmonary Disease, Chronic Obstructive1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)5
2CompletedTreatmentPulmonary Disease, Chronic Obstructive1
3CompletedNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)13
3CompletedTreatmentPulmonary Disease, Chronic Obstructive1
3RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3RecruitingTreatmentSmoking1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Moderate to Very Severe COPD1
4CompletedTreatmentPulmonary Disease, Chronic Obstructive3
4RecruitingBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailablePulmonary Disease, Chronic Obstructive2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Powder, meteredRespiratory (inhalation)
Powder, meteredRespiratory (inhalation)400 mcg
InhalantRespiratory (inhalation)400 ug/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6750226No2000-09-052020-09-05Us
US7078412No2000-07-162020-07-16Us
US9056100No2000-07-072020-07-07Us
US6681768No2002-08-072022-08-07Us
US8051851No2007-04-222027-04-22Us
US6071498No1996-06-212016-06-21Us
US5840279No1996-06-212016-06-21Us
USRE46417No2000-09-052020-09-05Us
US9333195No2000-07-072020-07-07Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityVery slightly soluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.00152 mg/mLALOGPS
logP3.07ALOGPS
logP0.45ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)10.35ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.76 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity141.33 m3·mol-1ChemAxon
Polarizability52.09 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9907
Blood Brain Barrier+0.8883
Caco-2 permeable-0.6509
P-glycoprotein substrateSubstrate0.7017
P-glycoprotein inhibitor INon-inhibitor0.8103
P-glycoprotein inhibitor IINon-inhibitor0.6449
Renal organic cation transporterInhibitor0.6092
CYP450 2C9 substrateNon-substrate0.7784
CYP450 2D6 substrateNon-substrate0.809
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateNon-inhibitor0.8536
CYP450 2C9 inhibitorNon-inhibitor0.8817
CYP450 2D6 inhibitorNon-inhibitor0.5813
CYP450 2C19 inhibitorNon-inhibitor0.8022
CYP450 3A4 inhibitorNon-inhibitor0.7154
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.808
Ames testNon AMES toxic0.7753
CarcinogenicityNon-carcinogens0.9292
BiodegradationReady biodegradable0.6794
Rat acute toxicity2.6182 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7765
hERG inhibition (predictor II)Non-inhibitor0.6484
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinuclidines. These are compounds containing a 1-azabicyclo[2.2.2]octane moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinuclidines
Sub Class
Not Available
Direct Parent
Quinuclidines
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Piperidines / Thiophenes / Tetraalkylammonium salts / Tertiary alcohols / Heteroaromatic compounds / Carboxylic acid esters / Azacyclic compounds
show 9 more
Substituents
Phenoxy compound / Phenol ether / Quinuclidine / Alkyl aryl ether / Monocyclic benzene moiety / Piperidine / Benzenoid / Tetraalkylammonium salt / Quaternary ammonium salt / Heteroaromatic compound
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aromatic ether, carboxylic ester, quaternary ammonium ion, thiophenes (CHEBI:65346)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Cazzola M, Page CP, Matera MG: Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Jun;14(9):1205-14. doi: 10.1517/14656566.2013.789021. Epub 2013 Apr 9. [PubMed:23566013]

Drug created on June 04, 2013 17:58 / Updated on May 21, 2018 17:37